Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1Phase 1 1

Status

Active not recruiting 3Recruiting 2Not yet recruiting 1Completed 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Pancreatic Neoplasms 1Pancreatic Ductal Adenocarcinoma 1Pancreatic Adenocarcinoma 1

Interventions

Specimen Handling 219pembrolizumab 199Magnetic Resonance Spectroscopy 197Carboplatin 173Cisplatin 139Biopsy 133Nivolumab 129Paclitaxel 115Radiotherapy 111Cyclophosphamide 111Gemcitabine 104durvalumab 90Dexamethasone 90atezolizumab 76Radiation 72Rituximab 71Lenalidomide 69Pemetrexed 66Doxorubicin 65Bevacizumab 65Docetaxel 62Ipilimumab 58Etoposide 57olaparib 55Fluorouracil 52venetoclax 50Taxes 50Radiosurgery 50Oxaliplatin 50Prednisone 49

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × Losartan × 90 days × Clear all
NCT05365893 2026-05-22

PHL Treatment in Pancreatic Cancer

Fox Chase Cancer Center

Phase EARLY_PHASE1 Active not recruiting
20 enrolled
Gastrointestinal

Pancreatic Ductal Adenocarcinoma

NCT04106856 2026-05-12

SHAPER

University of Utah

Phase 1 Active not recruiting
22 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT05077800 2026-04-13

FOLFIRINOX + Elraglusib + Losartan In Pancreatic Cancer

Massachusetts General Hospital

Phase 2 Active not recruiting
70 enrolled
Gastrointestinal

Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡